As outlined in the experimental plan shown in Fig. 8F, these in vivo experiments further validated that ISCU knockout in macrophages led to substantial tumor growth inhibition (Fig. 8G–I) and a reduction in Ki67+ tumor cells in mice (Supplementary Fig. 5G), particularly when combined with anti-PD-L1 therapy. Here, MKI67 is linked to neoplasm.